Cannabis Schedule III in 2026: Where Rescheduling Stands, How It's Reshaping the Business, and What Comes Next
The most consequential shift in federal cannabis policy in over five decades is unfolding right now—and the next major milestone is days away. On June 29, 2026, the DEA opens an expedited hearing that will decide whether the entirecannabis industry, including adult-use, gets the relief that medical operators have already started to see.
Here's a clear, current breakdown of where Schedule III stands, what it's already doing to the business, and where the road leads from here.
Where Schedule III stands right now
In April 2026, the federal government took its first concrete step toward reclassifying cannabis. Acting Attorney General Todd Blanche issued a final order moving two narrow categories of marijuana from Schedule I to Schedule III of the Controlled Substances Act:
Marijuana contained in an FDA-approved drug product, and
Marijuana subject to a state medical marijuana license.
The order took effect on April 28, 2026, and it traces back to a December 2025 executive order directing the Attorney General to expedite rescheduling.
One point cannot be overstated: this is not broad legalization. Adult-use (recreational) cannabis remains in Schedule I, and so does hemp-derived THC sold outside these channels. For now, only FDA-approved products and state-licensed medical cannabis enjoy Schedule III treatment.
The June 29 hearing: the milestone that matters most
The narrow April order set the stage. The June 29 hearing is where the bigger question gets decided.
The proceeding opens June 29, 2026, at 9:00 a.m. ET at the DEA Hearing Facility in Arlington, Virginia, and must conclude no later than July 15. It recesses July 3 and reconvenes July 6 in observance of the 250th Independence Day. Its purpose: to evaluate, through formal rulemaking, whether all forms of marijuana—not just medical—should move to Schedule III.
There is real controversy here that operators and the public should understand. The DEA denied participation to NORML and several other reform organizations, choosing to hear testimony primarily from parties supporting cannabis's continued Schedule I status. The agency reasoned that those groups did not meet the "interested person" criteria and that calls to remove cannabis from the CSA entirely fall outside the hearing's scope. Critics argue this leaves patients and consumers without a voice in a process that directly affects them.
How Schedule III is already affecting the cannabis business
280E tax relief is the headline
For decades, IRS Section 280E has been the single most punishing financial reality in cannabis. Because the plant sat in Schedule I, operators couldn't deduct ordinary business expenses—payroll, rent, marketing, professional fees—pushing effective federal tax rates above 70%, and for some operators past 75%.
That changed for medical operators. As of the April 2026 effective date, state-licensed medical cannabis is no longer subject to 280E. Qualifying businesses can now deduct standard operating expenses—an almost overnight transformation of medical cannabis economics.
The numbers are significant. Industry analysis estimates cannabis operators have overpaid roughly $2.24 billion in taxes compared to other industries because of 280E. Compliant dispensaries could see anywhere from $268,000 to $800,000 or more per location in additional annual after-tax cash flow.
The structuring trap operators need to understand
Here's the nuance driving the biggest decisions in the industry right now: 280E relief is tied to no longer trafficking in a Schedule I or II substance—not simply to holding a medical license. A business that operates in both medical and adult-use lanes is still trafficking in Schedule I as to its adult-use activity, so 280E continues to apply to that portion.
The practical takeaway: clean separation matters. Medical and adult-use revenue, expenses, inventory, and books need to be clearly segregated and well-documented to support any deductions claimed. Operators with mixed activity who blur that line are inviting audit risk.
The retroactivity question is the biggest open dollar item
The April order encouraged Treasury to consider retroactive 280E relief for prior tax years—but that's a suggestion, not a mandate, and the IRS has not committed to it. For most filers, FY2023, FY2022, and possibly FY2021 returns still fall within the statute of limitations.
Tax advisors are split across three positions: file amended returns now and claim relief; do nothing and wait; or—the move many consider most prudent—file inexpensive protective refund claims now to preserve the statute-of-limitations clock, then decide whether to perfect them once formal guidance lands. Whatever the choice, documenting the rationale and timeline now is what protects the position in a future audit.
There is at least one piece of good news on timing. Treasury has signaled forthcoming guidance will include a transition rule under which rescheduling first applies for the full taxable year that includes the effective date. For calendar-year filers, that means 280E relief applies as of January 1, 2026—eliminating the headache of splitting expenses mid-year.
The compliance cliff
Relief isn't automatic, and it isn't free of friction. The order created an expedited federal registration pathway: state licensees can submit existing state credentials as conclusive evidence of authorization when applying for DEA registration, with applications filed within the priority window processed on a faster track. The DEA's Medical Marijuana Dispensary Registration Portal opened April 29, 2026, with a $794 annual application fee.
The catch is the bar to clear. The substantive requirements point toward current Good Manufacturing Practice (cGMP) facilities, likely pharmaceutical-grade manufacturing standards, and tighter federally supervised supply-chain controls. Many small operators simply aren't built for that today—which means the tax windfall, real as it is, may arrive faster for well-capitalized businesses than for the independents who need it most.
What the future looks like
The path forward hinges on June 29 and what follows.
If the hearing leads to broader rescheduling and the resulting rule survives legal challenge, 280E falls away from the entire industry. The recreational market—which today carries the same 70-to-90% effective rates the medical side did—would move into ordinary business tax treatment. Analysts peg the value of that outcome in the high single-digit billions of dollars per year. If the process holds to the DOJ's aggressive timeline, a final rule could publish as soon as late 2026, though litigation could push that horizon out.
Two clouds are worth watching:
Legal challenges. Prohibitionist group Smart Approaches to Marijuana and the National Drug and Alcohol Screening Association have already sued to overturn the rescheduling. Expect scrutiny, too, of the legal theory behind the immediate order—the Acting Attorney General's use of treaty-implementation authority—which may face challenge in the courts.
The hemp definition change. Following the November 2025 continuing resolution, the federal definition of marijuana is set to broaden in November 2026 to capture certain THC-containing cannabinoids previously treated as hemp, narrowing hemp to products with no more than 0.3% THC.
And some things won't change regardless of the outcome: rescheduling does not override state marijuana or employment laws, and Department of Transportation drug-testing rules remain in effect.
The bottom line
Schedule III is no longer a distant "someday." For medical operators, the economics have already shifted—and the businesses that win will be the ones with clean books, a clear compliance posture, and a deliberate strategy on retroactive claims. For everyone else, June 29 is the date that determines how far this reform reaches.
The smart move right now is preparation, not celebration: separate your medical and adult-use activity, talk to your tax advisor about protective claims, evaluate the DEA registration pathway, and watch the hearing closely. The framework is being written this summer.
This article is for informational purposes only and does not constitute legal or tax advice. Cannabis laws and federal guidance are evolving rapidly; consult a licensed attorney or tax professional for guidance specific to your business.
Key sources
U.S. Department of Justice, Office of Public Affairs (April 2026 order announcement)
Federal Register: Rescheduling final rule (91 FR 22714) and Notice of Hearing (91 FR 22777)
DEA.gov, Marijuana Rescheduling Regulatory Actions
Foley Hoag LLP; Gibson Dunn; Duane Morris LLP; Seyfarth Shaw LLP (legal analyses)
Vicente LLP & Minority Cannabis Business Association (economic impact analysis)
NORML (hearing participation update)
